RedHill Biopharma Ltd. announced that the U.S. FDA has accepted for review the New Drug Application (NDA) for Talicia (RHB-105)1 for H. pylori infection. The NDA for Talicia has also been granted Priority Review designation and was assigned a target Prescription Drug User Act (PDUFA) action date by the FDA of November 2, 2019.
Commercial launch of Talicia with RedHill’s existing U.S. sales force is planned shortly following potential FDA approval. If approved, Talicia would be eligible for a total of eight years of U.S. market exclusivity.
“The efficacy of current standard-of-care therapies for H. pylori bacterial infection continues to decline due to the high and steadily increasing prevalence of antibiotic-resistant strains. This public health concern is widely recognized by the U.S. government and other leading health agencies, including the World Health Organization, which classified H. pylori as a Group I carcinogen and highlighted the urgent need for new treatments for H. pylori eradication,” said Dror Ben-Asher, Chief Executive Officer of RedHill Biopharma. “The acceptance for review of the NDA for Talicia and the Priority Review designation are encouraging steps as we continue our intensive preparations for a potential U.S. commercial launch of Talicia as a new first-line, standard-of-care therapy for H. pylori. We continue to work closely with the FDA, with the aim of bringing this important new therapy to patients.”
Breaking News
FDA Accepts RedHill Biopharma’s NDA for Talicia
Commercial launch of H. pylori treatment is planned shortly following potential FDA approval
07.16.19
Related Breaking News
-
Breaking News | Facilities | Industry News
CoreRx Fully Operational in New Product Development Center
Expansion gives CoreRx’s clients access to over 150,000 sq. ft. of space at the ICOT center campus.Contract Pharma Staff 08.10.20
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
Novavax and Serum Institute of India Announce Collaboration
Serum Institute gains exclusive rights to commercialize in India and non-exclusive rights to commercialize in other LMIC countries.Contract Pharma Staff 08.10.20
-
Breaking News | Collaborations & Alliances | Industry News
Pall Gets $4.9M DoD Contract to Build Ventilator Filter Mfg. Line
New line set to open in fall 2021.Contract Pharma Staff 08.10.20
-
Breaking News | Collaborations & Alliances | Industry News
Avacta Collaborates with Liverpool School of Tropical Medicine
Will clinically validate the coronavirus antigen test that Avacta is developing with Cytiva.Contract Pharma Staff 08.10.20
-
Breaking News | Industry News | Promotions & Moves
WuXi Vaccines Names Jian Dong as CEO
The vaccine CDMO is a joint venture between WuXi Biologics and Shanghai-based Hile Bio-Technology.08.10.20
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
U.S. Govt. Selects Grand River Aseptic Manufacturing to Help Combat COVID-19
HHS and Dept. of Defense call upon the U.S.-based CDMO to expand domestic fill/finish capacity under Operation Warp Speed.Contract Pharma Staff 08.10.20
-
Bio News | Breaking News | Facilities | Industry News | Parenterals
OncoGenerix & Alpha Capital to Build Injectables Factory in the U.S.
New project launches during ONGX Token STO Campaign.Contract Pharma Staff 08.10.20
-
Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances
Caprion-HistoGeneX Partners with Viroclinics-DDL
Will offer integrated, complementary services to advance infectious disease research and COVID-19 therapeutic development.Contract Pharma Staff 08.07.20
-
Breaking News | Promotions & Moves
ACG Appoints CEO of Inspection Business
Promotes Susheel Pillai to the position.Contract Pharma Staff 08.07.20
-
Breaking News | cGMP Manufacture | Industry News
Catalent’s Harmans Site Approved to Manufacture AveXis’ Gene Therapy
To produce commercial drug substance intermediate for AveXis’ spinal muscular atrophy gene therapy at its manufacturing facility in Harmans, MD.Contract Pharma Staff 08.07.20
-
Bioassay Development | Breaking News | Collaborations & Alliances | Scale-up/Technology Transfer
Avacta Partners with BBI Solutions
BBI will manufacture the rapid SARS-CoV-2 antigen test that is being developed.Contract Pharma Staff 08.07.20
-
Biologics, Proteins, Vaccines | Breaking News | Promotions & Moves
Valneva Appoints Chief Medical Officer
Juan Carlos Jaramillo will succeed Wolfgang Bender in October.Contract Pharma Staff 08.07.20
-
Breaking News | Cold Chain Management | Industry News | Packaging & Tracking
Medipal Holdings Partners with Cryoport
Will bring temperature-controlled supply chain solutions to the Japanese market.Contract Pharma Staff 08.06.20
-
Breaking News | Collaborations & Alliances | Industry News
Avid Selected to Lead Process Development of IOV-3001
Will provide process development, pilot-batch manufacturing & CGMP manufacturing services for Iovance Biotherapeutics.Contract Pharma Staff 08.06.20
-
Breaking News | Collaborations & Alliances | Industry News
Lonza Expands Facility in Switzerland
New facility will provide mid-scale commercial manufacturing to multiple customers and in particular, serve the growing needs of Servier.Contract Pharma Staff 08.06.20
